Medical Science Liaison
Pharvaris
Medical Science Liaison
Pharvaris
Develops oral bradykinin B2 antagonists
Pharvaris develops oral medications aimed at treating hereditary angioedema (HAE) and other bradykinin B2 receptor–mediated conditions. Its main focus is discovery and development of novel oral bradykinin B2 receptor antagonists that patients can take by mouth rather than by injection. The products work by blocking the bradykinin B2 receptor, which helps reduce or prevent swelling associated with these rare disorders. This approach sets Pharvaris apart from many current therapies that require injections, offering a convenient alternative for patients. The company operates in the clinical-stage biopharmaceutical space, pursuing regulatory approval and eventual commercialization of its oral therapies. Pharvaris’ goal is to provide effective, easier-to-use treatments that improve patient choice and quality of life for people with rare disease conditions.
Explore more opportunities at Pharvaris